Fri Sep 20 06:39:36 UTC 2024: ## Zoetis Stock Price Target Raised by Stifel Nicolaus
**New York, NY – September 20, 2024** – Equities research analysts at Stifel Nicolaus have increased their price target for Zoetis (NYSE:ZTS) from $200.00 to $210.00, representing a potential upside of 8.67% from the company’s current price. The brokerage maintains a “buy” rating on the stock.
This positive outlook follows a series of bullish reports from other analysts. BTIG Research raised their target price to $225.00 from $220.00, while Argus upgraded Zoetis to a “strong-buy” rating. Piper Sandler also boosted their price target to $210.00 from $195.00.
Overall, nine analysts have rated Zoetis with a “buy” rating, and one has issued a “strong buy” rating. MarketBeat data indicates an average rating of “Buy” and an average price target of $220.38.
Zoetis, a leading animal health company, recently exceeded analysts’ expectations for its second quarter earnings. The company reported earnings per share of $1.56, beating the consensus estimate of $1.49. Revenue for the quarter reached $2.36 billion, surpassing expectations of $2.31 billion.
Institutional investors and hedge funds continue to show confidence in Zoetis, with several increasing their stakes in the company. Hohimer Wealth Management LLC, Asset Dedication LLC, Angeles Wealth Management LLC, Forza Wealth Management LLC, and L. Roy Papp & Associates LLP all added shares of Zoetis during recent quarters.
Zoetis focuses on the development and commercialization of animal health medicines, vaccines, and diagnostic products for livestock and companion animals. The company operates globally and generates revenue across various species, including cattle, swine, poultry, fish, sheep, dogs, cats, and horses.
First Piper 